Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

In a recent study published in the Journal of Crohn’s and Colitis, researchers showed that oral vancomycin (OV) induces ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

It also explains the association between gallbladder polyps and cancer and looks at the treatment options. Share on Pinterest An ultrasound view of the gallbladder showing a polyp inside it.

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.